$PFE Recent News
Shire plunges, Balfour Beatty gains: European stock movers 5:01 a.m. Oct. 15, 2014 - Carla Mozee
Pfizer breast cancer treatment granted FDA priority review status 8:55 a.m. Oct. 13, 2014 - Chelsey Dulaney
The automaker the top performers like the most 12:15 p.m. Oct. 1, 2014 - Mark Hulbert
Do the top performers like any bond funds more than Bill Gross’ new fund? 11:30 a.m. Oct. 1, 2014 - Mark Hulbert
Copycat technology is the next big thing 8:51 a.m. Sept. 29, 2014 - Marek Fuchs
Actavis reportedly in talks to buy Salix Pharma 11:51 a.m. Sept. 24, 2014 - Russ Britt
Pfizer held takeover talks with Actavis 1:32 a.m. Sept. 24, 2014 - Jonathan D. Rockoff
CF Industries rises on merger talks; AstraZeneca, AbbVie fall 3:21 p.m. Sept. 23, 2014 - Sue Chang
Actavis shares rise on report of Pfizer approach 2:49 p.m. Sept. 23, 2014 - Ciara Linnane
Burger King, AbbVie among stocks hit by new tax inversion rules 2:40 p.m. Sept. 23, 2014 - Ben Eisen
Shire, AstraZeneca fall in London after U.S. tax move 12:19 p.m. Sept. 23, 2014 - Carla Mozee
The headwinds that Facebook faces 12:52 p.m. Sept. 11, 2014 - Mark Hulbert
Stock buybacks blamed for lack of U.S. prosperity 4:51 p.m. Sept. 2, 2014 - Russ Britt
Here’s what history says about the stock market in September 5:39 a.m. Sept. 2, 2014 - Mark Hulbert
Inversions are not such a sweet deal for fund investors 1:47 p.m. Aug. 18, 2014 - Chuck Jaffe
Tax inversions can be bad for shareholders — and for America 2:31 p.m. Aug. 17, 2014 - Chuck Jaffe
Investors sent on a wild ride by hostile deals 12:56 p.m. Aug. 15, 2014 - David Weidner
Timing this market is guaranteed to make you a loser 1:02 p.m. Aug. 8, 2014 - Mark Hulbert
Tax inversions help, not hurt, the economy 7:20 a.m. Aug. 8, 2014 - Diana Furchtgott-Roth
Mega caps with mega recommendations 7:54 a.m. Aug. 6, 2014 - Mark Hulbert
Guru Stocks at 52-Week Lows: GOOG, PFE, UN, E, MTU 59 min ago - GuruFocus.com
Dow Jones (DJIA) Today: Pfizer (PFE) Lower 11:00 a.m. Today - TheStreet.com
LabCorp launches new HIV test 10:40 a.m. Today - Seeking Alpha
5 Best Biotech Stocks to Buy Now 6:02 a.m. Today - InvestorPlace.com
FDA clears Pfizer's abuse deterrent pain med 5:20 p.m. Oct. 17, 2014 - Seeking Alpha
UPDATE: FDA Has Approved New Labeling on Pfizer's Embeda 3:27 p.m. Oct. 17, 2014 - benzinga.com
Belviq Sales Dip: What To Watch For Ahead 1:13 p.m. Oct. 17, 2014 - Seeking Alpha
Panel Votes to Keep Strong Warning on Smoking-Cessation Drug 5:58 p.m. Oct. 16, 2014 - The Wall Street Journal Interactive Edition
Ad Comm votes to retain Chantix label 3:56 p.m. Oct. 16, 2014 - Seeking Alpha
The 4 Stocks That Held the DJIA Down 3:25 p.m. Oct. 16, 2014 - 247WallSt.com
Baxter Q3 Beats As Hemophilia Drugs Fend Off Rivals 2:07 p.m. Oct. 16, 2014 - Investors Business Daily
3 Stocks Dragging In The Drugs Industry 1:22 p.m. Oct. 16, 2014 - TheStreet.com
Ad Comm meeting approaches for Novartis' psoriasis therapy candidate 11:46 a.m. Oct. 16, 2014 - Seeking Alpha
Shire Can Thrive Without AbbVie, Say Analysts 10:19 a.m. Oct. 16, 2014 - Investors Business Daily
Baxter’s Medical-Products Sales Rise 7:35 a.m. Oct. 16, 2014 - The Wall Street Journal Interactive Edition
AbbVie Flip-Flop Hands U.S. Government Tax-Deal Victory 12:36 a.m. Oct. 16, 2014 - The Wall Street Journal Interactive Edition
Dogs Of The Dow: 2014 Third Quarter Review 4:14 p.m. Oct. 15, 2014 - Seeking Alpha
Multiple Contraction Can Hit Pfizer 3:46 p.m. Oct. 15, 2014 - Seeking Alpha
Shire Falls, AbbVie Questioned On Buyout Backtrack 12:11 p.m. Oct. 15, 2014 - Investors Business Daily
Today's Market: Inversions, Tech Deals And Upgrades/Downgrades Moving These Names 11:32 a.m. Oct. 15, 2014 - Seeking Alpha
ViiV Healthcare Expands Program to Reduce HIV Disparities in Southern U.S. 9:00 a.m. Today - PR Newswire - PRF
Acquisition Updates, Drug Approval, Drug Development Discontinuation, and Contract Update - Research Reports on AbbVie, Gilead, Pfizer, Lilly and Aetna 8:35 a.m. Today - PR Newswire - PRF
Pfizer Announces FDA Acceptance Of Palbociclib New Drug Application With Priority Review 11:59 a.m. Oct. 13, 2014 - BusinessWire - BZX
Marketing Application Update, Acquisitions, Collaborations, FDA Approvals, and Structural Changes - Research Reports on Gilead, BD, Pfizer, AbbVie and Novartis 8:55 a.m. Oct. 10, 2014 - PR Newswire - PRF
Pfizer to Present New Data Evaluating Safety, Tolerability and Immunogenicity of its Investigational Staphylococcus aureus Vaccine Candidate at IDWeek 2014™ 8:00 a.m. Oct. 10, 2014 - BusinessWire - BZX
Top 10 Health Care Trends Report Finds Opportunities to Achieve "Triple Aim" 2:45 p.m. Oct. 9, 2014 - PR Newswire - PRF
Kane Biotech Appoints Mark Nawacki to the Board of Directors 8:06 a.m. Oct. 8, 2014 - Marketwired
Pfizer To Present Safety And Immunogenicity Data From A Phase 2 Study Of Its Investigational Meningococcal Group B Vaccine, Bivalent rLP2086, Co-Administered With A Licensed Human Papillomavirus Vaccine 8:01 a.m. Oct. 8, 2014 - BusinessWire - BZX
Portola Pharmaceuticals Announces Phase 3 ANNEXA(TM)-A Study of Andexanet Alfa and Eliquis (Apixaban) Met Primary and Secondary Endpoints With High Statistical Significance 8:00 a.m. Oct. 1, 2014 - GlobeNewswire
Positive Study Results, Acquisitions, Drug Approval, Regulatory Updates, and Collaborations - Research Reports on Gilead, Pfizer, AbbVie, Pacira and Thermo Fisher 8:50 a.m. Sept. 30, 2014 - PR Newswire - PRF
Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study 8:00 p.m. Sept. 29, 2014 - BusinessWire - BZX
Fitch Affirms Pfizer's IDR at 'A+'; Outlook Stable 3:30 p.m. Sept. 26, 2014 - BusinessWire - BZX
GlycoMimetics Announces a Delay in the Initiation of the Phase 3 Trial With Rivipansel 9:01 a.m. Sept. 26, 2014 - GlobeNewswire
Pain Therapeutics Expands Pipeline With FENROCK(TM), an Abuse-Deterrent Pain Patch 7:29 a.m. Sept. 26, 2014 - GlobeNewswire
Pfizer Completes Acquisition Of InnoPharma 8:00 a.m. Sept. 25, 2014 - BusinessWire - BZX
Active Equities to Watch in Pharma Industry - Pfizer, BioDelivery Sciences Intl., Repros Therapeutics, Catalent, and Nektar Therapeutics 8:30 a.m. Sept. 24, 2014 - PR Newswire - PRF
Pfizer Invites Public to View and Listen to Webcast of October 28 Conference Call with Analysts 10:39 a.m. Sept. 23, 2014 - BusinessWire - BZX
Kim Cattrall Encourages Women to Embrace Menopause with Style 8:00 a.m. Sept. 23, 2014 - BusinessWire - BZX
Licensing Agreements, Results of Clinical Trials, and Acquisitions - Research Reports on Gilead, AbbVie, Pfizer, Auxilium and Endo 9:05 a.m. Sept. 22, 2014 - PR Newswire - PRF
Bristol-Myers Squibb and Pfizer Announce Charitable Donations of More Than $1 Million to Support Cardiovascular Education for Patients and Caregivers 8:01 a.m. Sept. 22, 2014 - BusinessWire - BZX
Shire plunges, Balfour Beatty gains: European stock movers 5:01 a.m. Oct. 15, 2014 - Carla Mozee
Pfizer breast cancer treatment granted FDA priority review status 8:55 a.m. Oct. 13, 2014 - Chelsey Dulaney
The automaker the top performers like the most 12:15 p.m. Oct. 1, 2014 - Mark Hulbert
Do the top performers like any bond funds more than Bill Gross’ new fund? 11:30 a.m. Oct. 1, 2014 - Mark Hulbert
Copycat technology is the next big thing 8:51 a.m. Sept. 29, 2014 - Marek Fuchs
Actavis reportedly in talks to buy Salix Pharma 11:51 a.m. Sept. 24, 2014 - Russ Britt
Pfizer held takeover talks with Actavis 1:32 a.m. Sept. 24, 2014 - Jonathan D. Rockoff
CF Industries rises on merger talks; AstraZeneca, AbbVie fall 3:21 p.m. Sept. 23, 2014 - Sue Chang
Actavis shares rise on report of Pfizer approach 2:49 p.m. Sept. 23, 2014 - Ciara Linnane
Burger King, AbbVie among stocks hit by new tax inversion rules 2:40 p.m. Sept. 23, 2014 - Ben Eisen
Shire, AstraZeneca fall in London after U.S. tax move 12:19 p.m. Sept. 23, 2014 - Carla Mozee
The headwinds that Facebook faces 12:52 p.m. Sept. 11, 2014 - Mark Hulbert
Stock buybacks blamed for lack of U.S. prosperity 4:51 p.m. Sept. 2, 2014 - Russ Britt
Here’s what history says about the stock market in September 5:39 a.m. Sept. 2, 2014 - Mark Hulbert
Inversions are not such a sweet deal for fund investors 1:47 p.m. Aug. 18, 2014 - Chuck Jaffe
Tax inversions can be bad for shareholders — and for America 2:31 p.m. Aug. 17, 2014 - Chuck Jaffe
Investors sent on a wild ride by hostile deals 12:56 p.m. Aug. 15, 2014 - David Weidner
Timing this market is guaranteed to make you a loser 1:02 p.m. Aug. 8, 2014 - Mark Hulbert
Tax inversions help, not hurt, the economy 7:20 a.m. Aug. 8, 2014 - Diana Furchtgott-Roth
Mega caps with mega recommendations 7:54 a.m. Aug. 6, 2014 - Mark Hulbert
Guru Stocks at 52-Week Lows: GOOG, PFE, UN, E, MTU 59 min ago - GuruFocus.com
Dow Jones (DJIA) Today: Pfizer (PFE) Lower 11:00 a.m. Today - TheStreet.com
LabCorp launches new HIV test 10:40 a.m. Today - Seeking Alpha
5 Best Biotech Stocks to Buy Now 6:02 a.m. Today - InvestorPlace.com
FDA clears Pfizer's abuse deterrent pain med 5:20 p.m. Oct. 17, 2014 - Seeking Alpha
UPDATE: FDA Has Approved New Labeling on Pfizer's Embeda 3:27 p.m. Oct. 17, 2014 - benzinga.com
Belviq Sales Dip: What To Watch For Ahead 1:13 p.m. Oct. 17, 2014 - Seeking Alpha
Panel Votes to Keep Strong Warning on Smoking-Cessation Drug 5:58 p.m. Oct. 16, 2014 - The Wall Street Journal Interactive Edition
Ad Comm votes to retain Chantix label 3:56 p.m. Oct. 16, 2014 - Seeking Alpha
The 4 Stocks That Held the DJIA Down 3:25 p.m. Oct. 16, 2014 - 247WallSt.com
Baxter Q3 Beats As Hemophilia Drugs Fend Off Rivals 2:07 p.m. Oct. 16, 2014 - Investors Business Daily
3 Stocks Dragging In The Drugs Industry 1:22 p.m. Oct. 16, 2014 - TheStreet.com
Ad Comm meeting approaches for Novartis' psoriasis therapy candidate 11:46 a.m. Oct. 16, 2014 - Seeking Alpha
Shire Can Thrive Without AbbVie, Say Analysts 10:19 a.m. Oct. 16, 2014 - Investors Business Daily
Baxter’s Medical-Products Sales Rise 7:35 a.m. Oct. 16, 2014 - The Wall Street Journal Interactive Edition
AbbVie Flip-Flop Hands U.S. Government Tax-Deal Victory 12:36 a.m. Oct. 16, 2014 - The Wall Street Journal Interactive Edition
Dogs Of The Dow: 2014 Third Quarter Review 4:14 p.m. Oct. 15, 2014 - Seeking Alpha
Multiple Contraction Can Hit Pfizer 3:46 p.m. Oct. 15, 2014 - Seeking Alpha
Shire Falls, AbbVie Questioned On Buyout Backtrack 12:11 p.m. Oct. 15, 2014 - Investors Business Daily
Today's Market: Inversions, Tech Deals And Upgrades/Downgrades Moving These Names 11:32 a.m. Oct. 15, 2014 - Seeking Alpha
ViiV Healthcare Expands Program to Reduce HIV Disparities in Southern U.S. 9:00 a.m. Today - PR Newswire - PRF
Acquisition Updates, Drug Approval, Drug Development Discontinuation, and Contract Update - Research Reports on AbbVie, Gilead, Pfizer, Lilly and Aetna 8:35 a.m. Today - PR Newswire - PRF
Pfizer Announces FDA Acceptance Of Palbociclib New Drug Application With Priority Review 11:59 a.m. Oct. 13, 2014 - BusinessWire - BZX
Marketing Application Update, Acquisitions, Collaborations, FDA Approvals, and Structural Changes - Research Reports on Gilead, BD, Pfizer, AbbVie and Novartis 8:55 a.m. Oct. 10, 2014 - PR Newswire - PRF
Pfizer to Present New Data Evaluating Safety, Tolerability and Immunogenicity of its Investigational Staphylococcus aureus Vaccine Candidate at IDWeek 2014™ 8:00 a.m. Oct. 10, 2014 - BusinessWire - BZX
Top 10 Health Care Trends Report Finds Opportunities to Achieve "Triple Aim" 2:45 p.m. Oct. 9, 2014 - PR Newswire - PRF
Kane Biotech Appoints Mark Nawacki to the Board of Directors 8:06 a.m. Oct. 8, 2014 - Marketwired
Pfizer To Present Safety And Immunogenicity Data From A Phase 2 Study Of Its Investigational Meningococcal Group B Vaccine, Bivalent rLP2086, Co-Administered With A Licensed Human Papillomavirus Vaccine 8:01 a.m. Oct. 8, 2014 - BusinessWire - BZX
Portola Pharmaceuticals Announces Phase 3 ANNEXA(TM)-A Study of Andexanet Alfa and Eliquis (Apixaban) Met Primary and Secondary Endpoints With High Statistical Significance 8:00 a.m. Oct. 1, 2014 - GlobeNewswire
Positive Study Results, Acquisitions, Drug Approval, Regulatory Updates, and Collaborations - Research Reports on Gilead, Pfizer, AbbVie, Pacira and Thermo Fisher 8:50 a.m. Sept. 30, 2014 - PR Newswire - PRF
Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study 8:00 p.m. Sept. 29, 2014 - BusinessWire - BZX
Fitch Affirms Pfizer's IDR at 'A+'; Outlook Stable 3:30 p.m. Sept. 26, 2014 - BusinessWire - BZX
GlycoMimetics Announces a Delay in the Initiation of the Phase 3 Trial With Rivipansel 9:01 a.m. Sept. 26, 2014 - GlobeNewswire
Pain Therapeutics Expands Pipeline With FENROCK(TM), an Abuse-Deterrent Pain Patch 7:29 a.m. Sept. 26, 2014 - GlobeNewswire
Pfizer Completes Acquisition Of InnoPharma 8:00 a.m. Sept. 25, 2014 - BusinessWire - BZX
Active Equities to Watch in Pharma Industry - Pfizer, BioDelivery Sciences Intl., Repros Therapeutics, Catalent, and Nektar Therapeutics 8:30 a.m. Sept. 24, 2014 - PR Newswire - PRF
Pfizer Invites Public to View and Listen to Webcast of October 28 Conference Call with Analysts 10:39 a.m. Sept. 23, 2014 - BusinessWire - BZX
Kim Cattrall Encourages Women to Embrace Menopause with Style 8:00 a.m. Sept. 23, 2014 - BusinessWire - BZX
Licensing Agreements, Results of Clinical Trials, and Acquisitions - Research Reports on Gilead, AbbVie, Pfizer, Auxilium and Endo 9:05 a.m. Sept. 22, 2014 - PR Newswire - PRF
Bristol-Myers Squibb and Pfizer Announce Charitable Donations of More Than $1 Million to Support Cardiovascular Education for Patients and Caregivers 8:01 a.m. Sept. 22, 2014 - BusinessWire - BZX
